These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35123325)

  • 1. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study.
    Wallman P; Clark I; Taylor D
    J Psychiatr Res; 2022 Apr; 148():131-136. PubMed ID: 35123325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
    Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
    Wang GH; Svensson M; Shao H; Vouri SM; Park H
    J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
    [No Abstract]   [Full Text] [Related]  

  • 10. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 13. A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making.
    Pappa S; Barnett J; Mason K
    CNS Drugs; 2023 Jan; 37(1):107-116. PubMed ID: 36495380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
    Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
    J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: A 2-year naturalistic follow-up study.
    Clark I; Wallman P; Cornelius V; Taylor D
    Eur Psychiatry; 2021 Oct; 64(1):e68. PubMed ID: 34698007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation.
    Pappa S; Mason K; Howard E
    Int Clin Psychopharmacol; 2019 Nov; 34(6):305-311. PubMed ID: 31464804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.